<p>中国环球资产管理有限公司在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度将其在 Lyell Immunopharma, Inc.（NASDAQ:LYEL - 免费报告）中的持股比例减少了 94.9%。该机构投资者在本季度出售了 55,637 股后，持有该公司 2,966 股股票。中国环球资产管理有限公司在 Lyell Immunopharma 的持股在最近一个季度末的价值为 26,000 美元。</p>
<p>其他几家对冲基金最近也买卖了 LYEL 的股票。Almitas Capital LLC 在第一季度将其在 Lyell Immunopharma 的持股增加了 136.3%。Almitas Capital LLC 目前拥有 2,482,606 股该公司的股票，价值为 1,336,000 美元，此前在上个季度又购买了 1,432,086 股。ARCH Venture Management LLC 在第二季度获得了 Lyell Immunopharma 的新头寸，估计价值约为 16,113,000 美元。RBF Capital LLC 在第二季度购买了 Lyell Immunopharma 的新股份，价值约为 884,000 美元。Nuveen LLC 在第一季度获得了 Lyell Immunopharma 的新股份，价值约为 345,000 美元。最后，Bridgeway Capital Management LLC 在第二季度购买了 Lyell Immunopharma 的新头寸，估计价值约为 159,000 美元。目前 66.05% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>Lyell Immunopharma</strong> 警报：</p>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师最近对该公司发表了评论。HC Wainwright 将 Lyell Immunopharma 的评级从 “中性” 上调至 “买入”，并在 12 月 9 日的报告中将其目标价格从 20.00 美元提高至 45.00 美元。Wall Street Zen 在 9 月 1 日的研究报告中将 Lyell Immunopharma 的评级从 “卖出” 上调至 “持有”。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Lyell Immunopharma 的 “卖出（d-）” 评级。一位投资分析师对该股票给予了买入评级，而另一位则给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，平均目标价格为 45.00 美元。</p>
<p><strong>查看我们关于 Lyell Immunopharma 的最新报告</strong></p>
<h2>Lyell Immunopharma 价格表现</h2>
<p>NASDAQ:LYEL 的股票在周二开盘价为 32.40 美元。该公司的 50 日移动平均价格为 20.23 美元，200 日移动平均价格为 14.33 美元。Lyell Immunopharma, Inc.的年低为 7.65 美元，年高为 35.15 美元。该股票的市值为 6.8818 亿美元，市盈率为-1.41，贝塔值为-0.11。</p>
<p>Lyell Immunopharma（NASDAQ:LYEL - 获取免费报告）最近在 11 月 12 日宣布了其季度财报。该公司报告的每股收益（EPS）为（2.13 美元），超过分析师共识预期的（2.81 美元）0.68 美元。Lyell Immunopharma 的股本回报率为-96.68%，净利润率为-794,292.69%。该公司本季度的收入为 0.02 百万美元，而分析师的预期为 0.01 百万美元。分析师预计 Lyell Immunopharma, Inc.在当前财政年度的每股收益将为-0.78。</p>
<h2>Lyell Immunopharma 公司简介</h2>
<p>（免费报告）</p>
<p>Lyell Immunopharma, Inc.是一家临床阶段的细胞治疗公司，开发针对实体肿瘤患者的 T 细胞重编程技术。该公司利用体外基因重编程技术开发疗法，如 c Jun 过表达和 NR4A3 基因敲除，以赋予 T 细胞抵抗疲劳的能力；以及体外表观遗传重编程技术，包括 Epi R 以生成具有持久干性的人群 T 细胞，以及 Stim R，一种专有合成细胞模拟物。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票超过 Lyell Immunopharma</li>
<li>投资汽车股票</li>
<li>ServiceNow 的 70 亿美元赌注：恐慌还是机会？</li>
<li>什么使一只股票成为优质分红股票？</li>
<li>戴尔和惠普正在涨价——投资者应注意</li>
<li>技术股票解析：关于科技你需要知道的</li>
<li>为什么 DLocal 是 2026 年值得关注的顶级新兴市场金融科技股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
<p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Lyell Immunopharma 并不在名单上。</p>
<p>虽然 Lyell Immunopharma 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LYEL

<p>中国泛华资产管理有限公司在第二季度大幅减少了对 Lyell Immunopharma 的持股，降幅达到 94.9%，目前持有 2,966 股，价值 26,000 美元。其他对冲基金也调整了他们的持仓，其中一些增加了持股比例。分析师的评级意见不一，HC Wainwright 将评级上调至 “买入”，而其他分析师则维持 “持有” 或 “卖出” 评级。Lyell 的股票开盘价为 32.40 美元，市值为 6.8818 亿美元。该公司报告的第三季度收益好于预期，股本回报率为负 96.68%</p>

<p>China Universal Asset Management Co. Ltd. decreased its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 94.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,966 shares of the company's stock after selling 55,637 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Lyell Immunopharma were worth $26,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>中国环球资产管理有限公司在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度将其在 Lyell Immunopharma, Inc.（NASDAQ:LYEL - 免费报告）中的持股比例减少了 94.9%。该机构投资者在本季度出售了 55,637 股后，持有该公司 2,966 股股票。中国环球资产管理有限公司在 Lyell Immunopharma 的持股在最近一个季度末的价值为 26,000 美元。</p>
</div><p>Several other hedge funds have also recently bought and sold shares of LYEL. Almitas Capital LLC increased its position in shares of Lyell Immunopharma by 136.3% during the 1st quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after purchasing an additional 1,432,086 shares in the last quarter. ARCH Venture Management LLC acquired a new position in Lyell Immunopharma in the second quarter valued at about $16,113,000. RBF Capital LLC bought a new stake in Lyell Immunopharma during the second quarter worth about $884,000. Nuveen LLC acquired a new stake in shares of Lyell Immunopharma during the first quarter worth approximately $345,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of Lyell Immunopharma in the second quarter valued at approximately $159,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也买卖了 LYEL 的股票。Almitas Capital LLC 在第一季度将其在 Lyell Immunopharma 的持股增加了 136.3%。Almitas Capital LLC 目前拥有 2,482,606 股该公司的股票，价值为 1,336,000 美元，此前在上个季度又购买了 1,432,086 股。ARCH Venture Management LLC 在第二季度获得了 Lyell Immunopharma 的新头寸，估计价值约为 16,113,000 美元。RBF Capital LLC 在第二季度购买了 Lyell Immunopharma 的新股份，价值约为 884,000 美元。Nuveen LLC 在第一季度获得了 Lyell Immunopharma 的新股份，价值约为 345,000 美元。最后，Bridgeway Capital Management LLC 在第二季度购买了 Lyell Immunopharma 的新头寸，估计价值约为 159,000 美元。目前 66.05% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Lyell Immunopharma</strong> 警报：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts have recently commented on the company. HC Wainwright upgraded Lyell Immunopharma from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and increased their target price for the stock from $20.00 to $45.00 in a report on Tuesday, December 9th. Wall Street Zen raised Lyell Immunopharma from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Monday, September 1st. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Lyell Immunopharma in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and an average target price of $45.00.</p>
<div class="lb-trans"><p>几位分析师最近对该公司发表了评论。HC Wainwright 将 Lyell Immunopharma 的评级从 “中性” 上调至 “买入”，并在 12 月 9 日的报告中将其目标价格从 20.00 美元提高至 45.00 美元。Wall Street Zen 在 9 月 1 日的研究报告中将 Lyell Immunopharma 的评级从 “卖出” 上调至 “持有”。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Lyell Immunopharma 的 “卖出（d-）” 评级。一位投资分析师对该股票给予了买入评级，而另一位则给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，平均目标价格为 45.00 美元。</p>
</div><p><strong>View Our Latest Report on Lyell Immunopharma</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Lyell Immunopharma 的最新报告</strong></p>
</div><h2>Lyell Immunopharma Price Performance</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 价格表现</h2>
</div><p>Shares of NASDAQ:LYEL opened at $32.40 on Tuesday. The company's 50-day moving average price is $20.23 and its two-hundred day moving average price is $14.33. Lyell Immunopharma, Inc. has a one year low of $7.65 and a one year high of $35.15. The stock has a market capitalization of $688.18 million, a PE ratio of -1.41 and a beta of -0.11.</p>
<div class="lb-trans"><p>NASDAQ:LYEL 的股票在周二开盘价为 32.40 美元。该公司的 50 日移动平均价格为 20.23 美元，200 日移动平均价格为 14.33 美元。Lyell Immunopharma, Inc.的年低为 7.65 美元，年高为 35.15 美元。该股票的市值为 6.8818 亿美元，市盈率为-1.41，贝塔值为-0.11。</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.81) by $0.68. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.01 million. On average, analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Lyell Immunopharma（NASDAQ:LYEL - 获取免费报告）最近在 11 月 12 日宣布了其季度财报。该公司报告的每股收益（EPS）为（2.13 美元），超过分析师共识预期的（2.81 美元）0.68 美元。Lyell Immunopharma 的股本回报率为-96.68%，净利润率为-794,292.69%。该公司本季度的收入为 0.02 百万美元，而分析师的预期为 0.01 百万美元。分析师预计 Lyell Immunopharma, Inc.在当前财政年度的每股收益将为-0.78。</p>
</div><h2>Lyell Immunopharma Company Profile</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.</p>
<div class="lb-trans"><p>Lyell Immunopharma, Inc.是一家临床阶段的细胞治疗公司，开发针对实体肿瘤患者的 T 细胞重编程技术。该公司利用体外基因重编程技术开发疗法，如 c Jun 过表达和 NR4A3 基因敲除，以赋予 T 细胞抵抗疲劳的能力；以及体外表观遗传重编程技术，包括 Epi R 以生成具有持久干性的人群 T 细胞，以及 Stim R，一种专有合成细胞模拟物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
<li>Investing In Automotive Stocks</li>
<li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>Dell and HP Are Raising Prices—And Investors Should Take Note</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Lyell Immunopharma</li>
<li>投资汽车股票</li>
<li>ServiceNow 的 70 亿美元赌注：恐慌还是机会？</li>
<li>什么使一只股票成为优质分红股票？</li>
<li>戴尔和惠普正在涨价——投资者应注意</li>
<li>技术股票解析：关于科技你需要知道的</li>
<li>为什么 DLocal 是 2026 年值得关注的顶级新兴市场金融科技股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=LYEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Lyell Immunopharma 并不在名单上。</p>
</div><p>While Lyell Immunopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lyell Immunopharma 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

中国环球资产管理有限公司在 Lyell Immunopharma, Inc. $LYEL 持有价值 26000 美元的头寸